XBiotech Announces Positive Final Phase II Efficacy Results for TASKIN Study in Refractory Metastatic Colorectal Cancer

Article summary

XBiotech reported that the investigator-initiated TASKIN Phase II study of its monoclonal antibody, Vilamakitug (XB2001), met its primary efficacy endpoint with a 12-month overall survival rate of 61.3%.